4.6 Article

Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells

期刊

CELLULAR SIGNALLING
卷 26, 期 1, 页码 141-148

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2013.09.018

关键词

Hepatic stellate cells; miR-33a; TGF-beta 1; alpha-smooth muscle actin; PI3K/Akt; PPAR-alpha

向作者/读者索取更多资源

MicroRNAs (miRNAs) attract more attention in the pathophysiology of liver fibrosis and miR-33a has been previously demonstrated as involved in the regulation of cholesterol and lipid metabolism. Transforming growth factor-betal (TGE-beta 1) is generally accepted to be the main stimulating factor in the hepatic stellate cells (HSCs) activation, which plays an important role in hepatic fibrosis. However, the involvement and underlying mechanism of miR-33a and its role in TOE-beta 1-induced hepatic fibrogenesis remains unknown. Here, we investigate the role of miR-33a in the activation of immortalized human HSCs, Lx-2 cells. Our findings have shown that the expression of miR-33a with its host gene sterol regulatory element-binding protein 2 (SREBP2) was more highly expressed in activation of Lx-2 cells than in quiescent cells. The expression of miR-33a on TGE-beta 1-induced HSCs activation may be modulated via the activation of PI3K/Akt pathway. In addition, miR-33a significantly correlated with TGE-beta 1-induced expression of alpha 1 (I) collagen (CollA1) and alpha-SMA in HSCs. Bioinformatics analyses predict that peroxisome proliferator activated receptor-alpha (PPAR-alpha) is the potential target of miR-33a. We further found that anti-miR-33a significantly increases target gene PPAR-a mRNA and protein level, suggesting that miR-33a involved in HSCs function might be modulated by targeting PPAR-alpha. Finally, our results indicate that the expression of miR-33a increased with the progression of liver fibrosis. These results suggested that anti-miR-33a inhibit activation and extracellular matrix production, at least in part, via the activation of PI3K/Akt pathway and PPAR-alpha and anti sense of miR-33a may be a novel potential therapeutic approach for treating hepatic fibrosis in the future. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据